← Back to Clinical Trials
Recruiting NCT06671795

NCT06671795 ICU Biobank: Understanding Post-Intensive Care Syndrome (PICS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06671795
Status Recruiting
Phase
Sponsor Medical University of Vienna
Condition Post-Intensive Care Syndrome (PICS)
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2024-01-28
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2024-01-28 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to explore the development and progression of Post-Intensive Care Syndrome (PICS) in adult ICU patients by establishing a biobank of biological samples and outcome data. This biobank-based research is designed to investigate the physical, cognitive, and psychological health outcomes of ICU survivors and their relationship with potential biomarkers. The study population includes adult ICU patients aged 18-65, who have stayed in the ICU for at least 48 hours. The main questions it aims to answer are: What is the incidence of PICS and its main components? What risk factors are associated with the development of PICS six months post-ICU discharge? What are the long-term effects of ICU admission on quality of life, cognitive health, and physical function? Participants will: Provide blood samples during ICU admission and at follow-up visits at 4-5 weeks, 6 months, and 10-12 months after discharge. Complete assessments measuring quality of life, cognitive health, anxiety, depression, PTSD symptoms, physical function, and pulmonary function. Participate in three follow-up visits at the ICU Recovery Clinic after discharge to monitor PICS symptoms and recovery progress. This study does not involve an intervention but will gather data that could improve our understanding of PICS and inform strategies for post-ICU care. The data collected will be crucial for identifying PICS biomarkers and will contribute to developing targeted, personalized interventions for ICU survivors in the future.

Eligibility Criteria

Inclusion Criteria: * ICU stay of at least 48 hours * Age between 18 and 65 years at the time of ICU admission * Written informed consent Exclusion Criteria: * Transfer from another ICU outside of the Medical University of Vienna * Patient with a legal guardian * Homelessness * Place of residence outside of Austria

Contact & Investigator

Central Contact

Akos Tiboldi, Dr.med.univ.

✉ akos.tiboldi@meduniwien.ac.at

📞 +4314040041000

Frequently Asked Questions

Who can join the NCT06671795 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Post-Intensive Care Syndrome (PICS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06671795 currently recruiting?

Yes, NCT06671795 is actively recruiting participants. Contact the research team at akos.tiboldi@meduniwien.ac.at for enrollment information.

Where is the NCT06671795 trial being conducted?

This trial is being conducted at Vienna, Austria.

Who is sponsoring the NCT06671795 clinical trial?

NCT06671795 is sponsored by Medical University of Vienna. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology